Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from WuXi AppTec Co., Ltd. Class H ( (HK:2359) ) is now available.
WuXi AppTec Co., Ltd. announced that its board of directors will convene on April 27, 2026 to review and approve the Group’s first-quarter results for the period ended March 31, 2026. The board meeting will also authorize the publication of these quarterly figures, setting expectations for upcoming financial disclosure that may inform investors’ views on the company’s operational momentum and near-term performance.
The company disclosed the current composition of its board, which includes executive, non-executive, and independent non-executive directors, underscoring its established governance structure. This board makeup highlights a mix of management and independent oversight that will guide the review of results and ensure that forthcoming disclosures are considered under a structured corporate governance framework.
The most recent analyst rating on (HK:2359) stock is a Buy with a HK$150.00 price target. To see the full list of analyst forecasts on WuXi AppTec Co., Ltd. Class H stock, see the HK:2359 Stock Forecast page.
More about WuXi AppTec Co., Ltd. Class H
WuXi AppTec Co., Ltd. is a China-incorporated joint stock company listed in Hong Kong and operates as a global contract research, development, and manufacturing organization serving the pharmaceutical and biotech industries. The Group provides integrated R&D services that support drug discovery and development for clients worldwide, reinforcing its role within the life sciences and healthcare innovation ecosystem.
Average Trading Volume: 5,022,159
Technical Sentiment Signal: Buy
Current Market Cap: HK$359.5B
Learn more about 2359 stock on TipRanks’ Stock Analysis page.